MP14-Infectious Diseases. HIV
Precision Medicine / IBS-MP14 / Consolidated
Clinical research group focused on infectious pathology: HIV, HCV hepatitis, and osteoarticular infection. OBJECTIVES: To assess long-term adverse effects of antiretroviral drugs currently in use; Efficacy-safety research of new anti-HIV and anti-HCV drug targets; Investigation of prognostic factors of virological response to these diseases. Determination of the efficacy of antibiotics in cement spacers as a treatment for osteoarticular infection: development of pharmacokinetic models of antibiotics in various prosthetic materials.
Keywords
HIV, HCV, Osteoarticular Infection
MIGUEL ANGEL LOPEZ ZUNIGA
SVETLANA SADYRBAEVA DOLGOVA
CRISTINA LOPEZ ESPADA
Mª ANGELES MARTINEZ PEREZ
CAROLINA MERIDA FERNANDEZ
LEOPOLDO MUÑOZ MEDINA
PETER BROWN MORENO
JUAN PASQUAU LIANO
PABLO PEREZ VALLECILLOS
MARIA JOSE ROJAS VILCHEZ
VALME SANCHEZ CABRERA
ANTONIO TAPIA GOMEZ
DAVID VINUESA GARCIA
JOSE FERNANDO FLORIDO LOPEZ
CORAL GARCIA VALLECILLOS
VICENTE GARCIA ROSPIDE
EMILIO GUIRAO ARRABAL
JOSE HERNANDEZ I WANT
CARMEN HIDALGO TENORIO
ROSARIO JAVIER MARTINEZ
Mª ANGELES LARA JIMENEZ
MIGUEL ANGEL LOPEZ RUZ
EN-DALBACEN 2.0 Cohort: real-life study of dalbavancin as sequential/consolidation therapy in patients with infective endocarditis due to Gram-positive cocci
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2023;
FI: 10,8; Q1
Role of Low-Risk HPV PCR Monoinfection in Screening for HSIL and Anal Cancer in Men Who Have Sex with Men Living with HIV
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023;
FI: 6,208; Q1
The Challenge of Bacteremia Treatment due to Non-Fermenting Gram-Negative Bacteria
MICROORGANISMS, 2023;
FI: 4,5; Q2
Monkeypox Virus Infection and Sexually Transmitted Infections: A Cross-Sectional Study from a Secondary Hospital in the May-September 2022 International Outbreak
AIDS RESEARCH AND HUMAN RETROVIRUSES, 2023;
FI: 1,5; Q4
Isolation of Haemophilus no ducreyi in samples from the genital tract of men: Its clinical relationship
International Journal of Andrology, 2023;
FI: 0,8; Q4
High efficacy of glecaprevir/pibrentasvir for HCV-infected individuals with active drug use
JOURNAL OF INFECTION, 2022;
FI: 38,637; D1
Tenofovir Alafenamide Plasma Concentrations Are Reduced in Pregnant Women Living With Human Immunodeficiency Virus (HIV): Data From the PANNA Network
CLINICAL INFECTIOUS DISEASES, 2022;
FI: 20,999; D1
Identification of IL-6 Signaling Components as Predictors of Severity and Outcome in COVID-19
FRONTIERS IN IMMUNOLOGY, 2022;
FI: 8,786; Q1
Major Histocompatibility Complex Class I Chain-Related alpha (MICA) STR Polymorphisms in COVID-19 Patients
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022;
FI: 6,208; Q1
On lung ultrasound scoring for the early evaluation of patients with COVID-19 and dyspnea
EMERGENCIES, 2022;
FI: 5,345; Q1
A proportion of CD4(+) T cells from patients with chronic Chagas disease undergo a dysfunctional process, which is partially reversed by benznidazole treatment
PLOS NEGLECTED TROPICAL DISEASES, 2021;
FI: 4,411; D1
Characteristics and Outcome of Acute Heart Failure in Infective Endocarditis: Focus on Cardiogenic Shock
CLINICAL INFECTIOUS DISEASES, 2021;
FI: 9,079; D1
Anakinra after treatment with corticosteroids alone or with tocilizumab in patients with severe COVID-19 pneumonia and moderate hyperinflammation. A retrospective cohort study.
INTERNAL AND EMERGENCY MEDICINE, 2021;
FI: 3,397; Q2
Anakinra after treatment with corticosteroids alone or with tocilizumab in patients with severe COVID-19 pneumonia and moderate hyperinflammation. A retrospective cohort study: reply.-
INTERNAL AND EMERGENCY MEDICINE, 2021;
FI: 3,397; Q2
Blood culture-negative infective endocarditis: a worse outcome? Results from a large multicentre retrospective Spanish cohort study
INFECTIOUS DISEASES, 2021;
FI: 3,404; Q3
Necrotizing Sarcoid Granulomatosis: A Disease Not to be Forgotten
CASE REPORTS IN MEDICINE, 2020;
Negative Clinical Evolution in COVID-19 Patients Is Frequently Accompanied With an Increased Proportion of Undifferentiated Th Cells and a Strong Underrepresentation of the Th1 Subset
FRONTIERS IN IMMUNOLOGY, 2020;
FI: 5,085; Q1
Genetic diversity of HIV in seminal plasma remains higher than in blood after short-term antiretroviral therapy.
SEXUALLY TRANSMITTED INFECTIONS, 2020;
FI: 3,396; Q2
Dalbavancin is a novel antimicrobial against Gram-positive pathogens: clinical experience beyond labeled indications
EUROPEAN JOURNAL OF HOSPITAL PHARMACY-SCIENCE AND PRACTICE, 2020;
FI: 0,892; Q4
Migration and Surgical Retrieval of an Amplatzer Septal Occluder into Abdominal Aorta
ANNALS OF VASCULAR SURGERY, 2020;
FI: 1,125; Q4
A Parasite Biomarker Set for Evaluating Benznidazole Treatment Efficacy in Patients with Chronic Asymptomatic Trypanosoma cruzi Infection
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2019;
FI: 4,715; D1
Antimicrobial management of Tropheryma whipplei endocarditis: the Spanish Collaboration on Endocarditis (GAMES) experience
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2019;
FI: 5,113; D1
High efficacy of resistance-guided treatment of HCV patients failing NS5A inhibitors in the real world
Journal of Hepatology, 2019;
FI: 18,946; D1
Outpatient Parenteral Antibiotic Treatment for Infective Endocarditis: A Prospective Cohort Study From the GAMES Cohort
CLINICAL INFECTIOUS DISEASES, 2019;
FI: 9,055; D1
An Atypical Radiological Presentation of Lung Adenocardnoma
ARCHIVES DE BRONCONEUMOLOGIA, 2019;
FI: 4,214; Q1
Neurocognitive safety after 96 weeks on dual therapy with atazanavir / ritonavir plus lamivudine: results of the neurocognitive substudy of the SALT randomized clinical trial
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2018;
FI: 5,217; D1
High quality of life, treatment tolerability, safety and efficacy in HIV patients switching from triple therapy to lopinavir / ritonavir monotherapy: A randomized clinical trial
PLOSONE, 2018;
FI: 2,766; Q1
Prognostic implications of a negative echocardiography in patients with infective endocarditis
EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2018;
FI: 3,282; Q1
Immune Correlates of Natural HIV Elite Control and Simultaneous HCV Clearance - Supercontrollers
FRONTIERS IN IMMUNOLOGY, 2018;
FI: 5,511; Q1
Human Immunodeficiency Virus / Hepatits C Virus Coinfection in Spain: Elimination Is Feasible, but the Burden of Residual Cirrhosis Will Be Significant
OPEN FORUM INFECTIOUS DISEASES, 2018;
FI: 3,24; Q2
Two Cases of Neisseria meningitidis Proctitis in HIV-Positive Men Who Have Sex with Men
EMERGING INFECTIOUS DISEASES, 2017;
FI: 8,222; D1
Adaptation of targeted nanocarriers to changing requirements in antimalarial drug delivery
NANOMEDICINE-NANOTECHNOLOGY BIOLOGY AND MEDICINE, 2017;
FI: 5,72; D1
Simplification to dual therapy (atazanavir / ritonavir plus lamivudine) versus standard triple therapy [atazanavir / ritonavir plus two nucleos (t) ides] in virologically stable patients on antiretroviral therapy: 96 week results from an open-label, non-inferiority, randomized clinical trial (SALT study)
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2017;
FI: 5,071; D1
High prevalence and diversity of HIV-1 non-B genetic forms due to immigration in southern Spain: A phylogeographic approach
PLOSONE, 2017;
FI: 2,806; Q1
Changes in the soil bacterial community along a pedogenic gradient
SCIENTIFIC REPORTS, 2017;
FI: 4,259; Q1
Protease inhibitor monotherapy is effective in controlling human immunodeficiency virus 1 shedding in the male genital tract.
CLINICAL MICROBIOLOGY AND INFECTION, 2016;
FI: 5,768; D1
Effectiveness of Ritonavir-Boosted Protease Inhibitor Monotherapy in Clinical Practice Even with Previous Virological Failures to Protease Inhibitor-Based Regimens
PLOSONE, 2016;
FI: 3,234; Q1
Vancomycin does not remain appropriate empiric therapy in coagulase-negative staphylococcal bacteremia.
JOURNAL OF INFECTION, 2016;
FI: 4,441; Q1
New Approaches to Overcome Transport Related Drug Resistance in Trypanosomatid Parasites
FRONTIERS IN PHARMACOLOGY, 2016;
FI: 4,418; Q1
Effect of Monotherapy with Darunavir / Ritonavir on Viral Load in Seminal Fluid, and Quality Parameters of Semen in HIV-1-Positive Patients
PLOSONE, 2016;
FI: 3,057; Q1
Could specific cell targeting overcome resistance associated with current treatments for African trypanosomiasis?
NANOMEDICINE, 2015;
FI: 5,413; D1
Nanobody conjugated PLGA nanoparticles for active targeting of African Trypanosomiasis
JOURNAL OF CONTROLLED RELEASE, 2015;
FI: 7,705; D1
Specific Cell Targeting Therapy Bypasses Drug Resistance Mechanisms in African Trypanosomiasis
PLOS PATHOGENS, 2015;
FI: 7,562; D1
Amide-controlled, one-pot synthesis of tri-substituted slurries generates structural diversity and analogues with trypanocidal activity
SCIENTIFIC REPORTS, 2015;
FI: 5,578; D1
Dual treatment with atazanavir-ritonavir plus lamivudine versus triple treatment with atazanavir-ritonavir plus two nucleos (t) ides in virologically stable patients with HIV-1 (SALT): 48 week results from a randomized, open-label, non-inferiority trial
LANCET INFECTIOUS DISEASES, 2015;
FI: 22,433; D1
Improving the diagnosis of hidden HIV infection and other sexually transmitted infections (STIs) by studying the contacts made by HIV-infected patients.
Funder: GILEAD SCIENCES EUROPE LTD
File number: GLD19_0113
Execution time: 23/03/2020 - 22/03/2022
PI: JUAN PASQUAU LIAÑO
PROOF OF CONCEPT CORIVER: IVERMECTIN AS ANTIVIRIC TREATMENT IN PATIENTS INFECTED BY SARS-COV2 (COVID19).
Funder: COUNCIL OF ECONOMIC TRANSFORMATION, INDUSTRY, KNOWLEDGE AND UNIVERSITIES
File number: CV20-75519
Execution time: 05/09/2020 - 04/02/2021
PI: CARMEN HIDALGO TENORIO
15_0078 - GILEAD - CARMEN HIDALGO - Training course on: Antiretroviral treatment strategies in different scenarios of HIV patients, naïve, simplification, switch Long-term toxicity control
Funder: GILEAD SCIENCES INTERNATIONAL LTD.
File number: 15_0078
Execution time: 05/10/2015 - 04/10/2016
PI: CARMEN HIDALGO TENORIO
RESEARCH IN PREVENTION OF CONGENITAL CHAGAS DISEASE: Parasitological, placental and immunological markers - ELAC2014 / HID0328
Funder: CARLOS III HEALTH INSTITUTE - FEDER
File number: AC15 / 00037
Execution time: 01/01/2016 - 31/12/2018
PI: JUAN PASQUAU LIAÑO
Identification and validation of biomarkers to improve the control of congenital Chagas disease
Funder: CARLOS III HEALTH INSTITUTE - FEDER
File number: AC18 / 00010
Execution time: 01/01/2019 - 31/12/2021
PI: JUAN PASQUAU LIAÑO
Phase IV clinical trial on the safety and immunogenicity of Gardasil-9 vaccine in HIV-infected adult women
Funder: CARLOS III HEALTH INSTITUTE - FEDER
File number: PI19 / 00283
Execution time: 01/01/2020 - 31/12/2022
PI: CARMEN HIDALGO TENORIO
Analysis of the suitability of the use of antibiotic prophylaxis in surgical procedures performed in Spain (ProA-Q)
Funder: SPANISH HOSPITAL PHARMACY FOUNDATION
Type of test: OBSERVATIONAL STUDY WITH MEDICATION
Execution time: 12/09/2023 - 28/02/2024
IP: SVETLANA SADYRBAEVA DOLGOVA
PseudoNOVA2 study. Design of optimized antimicrobial treatment guidelines for respiratory infections caused by Pseudomonas aeruginosa.
Funder: CONSORCI SANITARI MAR PARC DE SALUT DE BARCELONA
Type of test: OBSERVATIONAL STUDY WITH MEDICATION
Execution time: 22/11/2023 - 31/12/2025
PI: CARMEN HIDALGO TENORIO
Retrospective analysis of real-world use of cefiderocol for the treatment of Gram-negative infections as part of the early access program (PERSEUS study)
Funder: SHIONOGI SL
Type of test: OBSERVATIONAL STUDY WITH MEDICATION
Execution time: 09/02/2023 - 30/06/2023
PI: CARMEN HIDALGO TENORIO
Prospective observational study to evaluate the safety and effectiveness of two mixtures of modified allergenic extracts of Cupressus arizonica pollen with a mixture of 5 grass pollen or with Olea europaea pollen associated with microcrystalline tyrosine.
Financer: ALLERGY THERAPEUTICS IBERICA, SLU
Type of test: OBSERVATIONAL STUDY WITH MEDICATION
Execution time: 17/03/2023 - 31/12/2023
PI: JOSE FERNANDO FLORIDO LOPEZ
CABO-CHANCE: Real-life study on the use of long-acting cabotegravir/rilpivirine (CAB/RPV AP) in treatment-experienced patients living with HIV (PLHIV)
Funder: PUBLIC FOUNDATION FOR BIOSANITARY RESEARCH OF ORIENTAL ANDALUCIA ALEJANDRO OTERO (FIBAO)
Type of test: OBSERVATIONAL STUDY WITH MEDICATION
Execution time: 26/07/2023 - 30/09/2026
PI: CARMEN HIDALGO TENORIO
Adaptive, randomized, double-blind (sponsor-open), placebo-controlled study to investigate the antiviral effect, safety, tolerability, and pharmacokinetics of VH3739937 in treatment-naïve HIV-1 positive adults
Funder: VIIV HEALTHCARE UK LIMITED
Type of test: CLINICAL TRIAL WITH DRUGS
Execution time: 24/11/2023 - 30/10/2024
PI: CARMEN HIDALGO TENORIO
Multicenter, double-blind, randomized, placebo-controlled, parallel-group phase III clinical trial evaluating the clinical efficacy and safety of immunotherapy with the purified major allergen Cup a 1 in patients with allergic rhinoconjunctivitis.
Funder: DIATER DIAGNOSTIC AND THERAPEUTIC APPLICATIONS LABORATORY, SA
Type of test: CLINICAL TRIAL WITH DRUGS
Execution time: 16/05/2023 - 30/11/2024
PI: JOSE FERNANDO FLORIDO LOPEZ
Phase III, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of GS-5245 for the treatment of COVID-19 in participants at high risk of disease progression
Funder: GILEAD SCIENCES, SLU
Type of test: CLINICAL TRIAL WITH DRUGS
Execution time: 29/12/2022 - 05/12/2023
PI: CARMEN HIDALGO TENORIO
Retrospective, descriptive, multicenter study with chart review on cefiderocol in the treatment of patients with Acinetobacter spp infections. resistant to carbapenems. ARES
Funder: SHIONOGI BV
Test type: REST OF EEOO WITH MEDICATIONS
Execution time: 31/03/2022 - 30/04/2022
PI: CARMEN HIDALGO TENORIO
Retrospective Chart Review to Evaluate the Safety Profile of Ceftobiprole in Patients With Impaired Hepatic or Renal Function or Immunosuppression (RETRACE)
Financier: ADVANZ PHARMA SWITZERLAND SARL
Type of test: OBSERVATIONAL STUDY WITH MEDICATION
Execution time: 07/12/2022 - 31/12/2023
PI: CARMEN HIDALGO TENORIO
CEFTO-REALLIFE: real-life use of ceftobiprole in a Spanish multicenter hospital cohort.
Funder: PUBLIC FOUNDATION FOR BIOSANITARY RESEARCH OF ORIENTAL ANDALUCIA ALEJANDRO OTERO (FIBAO)
Type of test: INDEPENDENT POST-AUTHORIZATION STUDY
Execution time: 09/06/2022 - 30/12/2022
PI: CARMEN HIDALGO TENORIO
Non-inferiority randomized clinical trial to evaluate the efficacy and safety of short treatment of uncomplicated enterococcal bacteremia
Funder: ANDALUSIAN PUBLIC FOUNDATION FOR HEALTH RESEARCH MANAGEMENT OF SEVILLE
Type of test: INDEPENDENT CLINICAL TRIAL
Execution time: 11/03/2022 - 30/01/2025
IP: MIGUEL ANGEL LOPEZ RUZ
Efficacy and safety of 7 versus 14 days of antibiotic treatment for bacteremia caused by Pseudomonas aeruginosa: a multicenter, randomized clinical trial (SHORTEN-2) with a DOOR/RADAR analysis
Funder: ANDALUSIAN PUBLIC FOUNDATION FOR HEALTH RESEARCH MANAGEMENT OF SEVILLE
Type of test: INDEPENDENT CLINICAL TRIAL
Execution time: 24/01/2022 - 30/05/2025
IP: MIGUEL ANGEL LOPEZ ZUÑIGA
Efficacy and Safety of Intra-arterial Administration of REX-001 in the Treatment of Ischemic Ulcers in Patients With Rutherford Category 5 Potentially Dangerous Lower Extremity Chronic Ischemia and Diabetes Mellitus: A Pivotal, Adaptive, Placebo-Controlled Trial, double blind and with parallel groups.
Funder: IXAKA LIMITED
Type of test: COMMERCIAL CLINICAL TRIAL
Execution time: 04/04/2022 - 30/12/2025
IP: PABLO PEREZ VALLECILLOS
Phase 2, multicenter, randomized, double-blind (within dose level), placebo-controlled, parallel-group, dose-finding study to evaluate the efficacy and safety of TF0023 versus placebo in the treatment of COVID-19. XNUMX in hospitalized adults.
Funder: TECHFIELDS INC
Type of test: CLINICAL TRIAL WITH DRUGS
Execution time: 10/08/2022 - 30/01/2024
PI: JUAN PASQUAU LIAÑO
Phase I/II, (first-in-human), multicenter, randomized, single-blind, controlled dose-escalation study to evaluate the reactogenicity, safety, immunogenicity and efficacy of HBV vaccines based on GSK viral vectors Biologicals administered in a primary vaccination – booster schedule, with sequential or joint administration of an adjuvanted therapeutic protein vaccine (GSK3528869A) in patients with chronic hepatitis B (18-65 years), on treatment with nucleotide analogues (NA). (TH HBV VV-001)
Funder: GLAXOSMITHKLINE, SA
Type of test: COMMERCIAL CLINICAL TRIAL
Execution time: 28/04/2022 - 30/12/2023
IP: JOSE HERNANDEZ QUERO
Multicenter, Randomized, Controlled Phase III Trial to Determine the Efficacy and Safety of Two Dose Levels of Plitidepsin Compared to Control in Adult Patients Requiring Hospitalization for Medical Treatment of Moderate COVID-19 Infection
Financier: PHARMA MAR, SA
Type of test: COMMERCIAL CLINICAL TRIAL
Execution time: 11/01/2022 - 30/05/2022
PI: CARMEN HIDALGO TENORIO
ALLERGO DATA RECORD
Funder: SPANISH SOCIETY OF ALLERGY AND CLINICAL IMMUNOLOGY
Type of test: INDEPENDENT POST-AUTHORIZATION STUDY
Execution time: 25/05/2021 - 30/05/2026
PI: JOSE FERNANDO FLORIDO LOPEZ
Retrospective Observational Study on Dalbavancin Real-life Utilization in Diabetic Patients Suffering From Infections – DALBADIA Study
Financer: ANGELINI PHARMA ESPAÑA, SLU
Type of test: COMMERCIAL POST AUTHORIZATION STUDY
Execution time: 30/11/2021 - 30/06/2022
PI: JUAN PASQUAU LIAÑO
Real Life Study of Bictegravir, Emtricitabine and Tenofovir Alafenamide in HIV-1 infected treatment-naive patients using test and treat strategy. (BIC/NOW). FIB-BIC-2021-01.
Funder: PUBLIC FOUNDATION FOR BIOSANITARY RESEARCH OF ORIENTAL ANDALUCIA ALEJANDRO OTERO (FIBAO)
Type of test: INDEPENDENT POST-AUTHORIZATION STUDY
Execution time: 06/07/2021 - 30/05/2023
PI: CARMEN HIDALGO TENORIO
Real Life Study of Bictegravir, Emtricitabine and Tenofovir Alafenamide in HIV-1 infected treatment-naive patients using test and treat strategy. (BIC/NOW). FIB-BIC-2021-01
Funder: PUBLIC FOUNDATION FOR BIOSANITARY RESEARCH OF ORIENTAL ANDALUCIA ALEJANDRO OTERO (FIBAO)
Type of test: INDEPENDENT POST-AUTHORIZATION STUDY
Execution time: 06/07/2021 - 30/05/2023
PI: DAVID VINUESA GARCIA
Prospective observational study to evaluate the safety and effectiveness of immunotherapy with an olive and grass pollen allergoid in patients with seasonal allergic asthma. GOL study
Financer: ALLERGY THERAPEUTICS IBERICA, SLU
Type of test: COMMERCIAL POST AUTHORIZATION STUDY
Execution time: 06/08/2021 - 30/11/2022
PI: JOSE FERNANDO FLORIDO LOPEZ
CDC- Four-year effectiveness of covid-19 vaccines against severe disease and asymptomatic infection: the covidvac@spain study
Financing: FOUNDATION FOR BIOMEDICAL RESEARCH OF LA PAZ UNIVERSITY HOSPITAL
Type of test: INDEPENDENT POST-AUTHORIZATION STUDY
Execution time: 31/08/2021 - 31/08/2025
PI: CARMEN HIDALGO TENORIO
Pilot clinical trial to evaluate the efficacy, safety and tolerability of switching to treatment with Bictegravir/FTC/TAF (Biktarvy®) plus darunavir/cobicistat in heavily treated HIV-1 infected patients.
Financing: RIS ASSOCIATION (AIDS RESEARCH NETWORK)
Type of test: INDEPENDENT CLINICAL TRIAL
Execution time: 21/01/2021 - 30/04/2022
PI: CARMEN HIDALGO TENORIO
A PHASE II/III, DOUBLE-BLIND, TWO-GROUP INTERVENTIONAL STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORALLY ADMINISTERED PF-07321332/RITONAVIR COMPARED TO PLACEBO IN SYMPTOMATIC NON-HOSPITALIZED ADULT PATIENTS WITH COVID-19 WHO HAVE
Funder: PFIZER, SLU
Type of test: COMMERCIAL CLINICAL TRIAL
Execution time: 03/08/2021 - 30/03/2022
PI: JUAN PASQUAU LIAÑO
Phase III multicenter, randomized, controlled trial to determine the efficacy and safety of two dose levels of Plitidepsin compared to control in adult patients requiring hospitalization for medical treatment of
Financier: PHARMA MAR, SA
Type of test: COMMERCIAL CLINICAL TRIAL
Execution time: 25/08/2021 - 30/09/2021
IP: JOSE HERNANDEZ QUERO
Clinical trial of efficacy and safety, prospective, multicenter, randomized, double-blind, placebo-controlled, with subcutaneous immunotherapy in patients with rhinitis/rhinocojunctivitis with or without mild to moderate asthma sensitized to grasses and/or
Financer: INMUNOTEK, SL
Type of test: COMMERCIAL CLINICAL TRIAL
Execution time: 18/12/2020 - 30/09/2022
PI: JOSE FERNANDO FLORIDO LOPEZ
AN INTERVENTIONAL EFFICACY AND SAFETY, PHASE 2/3, DOUBLE-BLIND, 2-ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED PF-07321332/RITONAVIR COMPARED WITH PLACEBO IN NONHOSPITALIZED SYMPTOMATIC ADULT PARTICIPANTS WITH COVID-19 WHO ARE AT INCREASED RISK OF PROGRESSION
Funder: PFIZER, SLU
Type of test: COMMERCIAL CLINICAL TRIAL
Execution time: 03/08/2021 - 30/09/2022
PI: JUAN PASQUAU LIAÑO
Phase II/III, randomized, double-blind, double-dummy, placebo-controlled study to evaluate the safety and efficacy of 2 regimens of FP -07321332/Ritonavir administered orally to prevent symptoms of SARS -COV infection -
Funder: PFIZER, SLU
Type of test: COMMERCIAL CLINICAL TRIAL
Execution time: 23/09/2021 - 30/12/2021
PI: JUAN PASQUAU LIAÑO
Randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of ambrisenttan in patients with severe COVID-19.
Funder: NOORIK BIOPHARMACEUTICALS AG
Type of test: COMMERCIAL CLINICAL TRIAL
Execution time: 26/02/2021 - 30/10/2021
PI: CARMEN HIDALGO TENORIO
Randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of ambrisenttan in patients with severe COVID-19
Funder: NOORIK BIOPHARMACEUTICALS AG
Type of test: COMMERCIAL CLINICAL TRIAL
Execution time: 26/02/2021 - 30/10/2021
IP: JOSE HERNANDEZ QUERO
CDC -Prevention of the development of sars-cov-2 (covid-19) disease by prophylactic administration of emtricitabine / tenofovir disoproxil and hydroxychloroquine in high-risk healthcare personnel: randomized, pl-controlled clinical trial
Funder: NATIONAL PLAN ON AIDS
Type of test: INDEPENDENT CLINICAL TRIAL
Execution time: 06/04/2020 - 06/04/2021
PI: JUAN PASQUAU LIAÑO
CDC -Prevention of the development of sars-cov-2 (covid-19) disease by prophylactic administration of emtricitabine / tenofovir disoproxil and hydroxychloroquine in high-risk healthcare personnel: randomized clinical trial,
Funder: NATIONAL PLAN ON AIDS
Type of test: INDEPENDENT CLINICAL TRIAL
Execution time: 07/04/2020 - 07/04/2021
PI: LEOPOLDO MUÑOZ MEDINA
Substitution of Dolutegravir for Raltegravir 1200 mg QD in HIV-infected patients who develop neuropsychiatric symptoms after initiating triple therapy. Pilot clinical study (Neuropsiquiatric Evolution After Introduction of Raltegravir QD in subs
Funder: ANDALUSIAN PUBLIC FOUNDATION FOR MALAGA RESEARCH IN BIOMEDICINE AND HEALTH
Type of test: INDEPENDENT CLINICAL TRIAL
Execution time: 23/07/2020 - 30/06/2022
PI: CARMEN HIDALGO TENORIO
Dalbalencia in real clinical practice in Spain. a two-year retrospective study.
Funder: ANGELINI PHARMA ESPAÑA, SL
Type of test: COMMERCIAL POST AUTHORIZATION STUDY
Execution time: 07/04/2020 - 07/10/2020
PI: JUAN PASQUAU LIAÑO
Clinical and microbiological study on the impact of multidrug resistance on virulence and host response to Pseudomonas aeruginosa infection.
Funder: CONSORCI SANITARI MAR PARC DE SALUT DE BARCELONA
Type of test: INDEPENDENT POST-AUTHORIZATION STUDY
Execution time: 12/03/2020 - 30/12/2022
PI: CARMEN HIDALGO TENORIO
Efficacy of intravenous fosfomycin in complicated urinary tract infection with real-life conditions. Impact of MIC and baseline mutations. FOSFO-MIC project
Funder: ANDALUSIAN PUBLIC FOUNDATION FOR HEALTH RESEARCH MANAGEMENT OF SEVILLE
Type of test: INDEPENDENT POST-AUTHORIZATION STUDY
Execution time: 31/01/2020 - 30/03/2021
PI: DAVID VINUESA GARCIA
Phase II study to evaluate the tolerability, safety and efficacy of sublingual immunotherapy in patients with allergy to grass pollen.
Funder: ROXALL MEDICINA ESPAÑA, SA
Type of test: COMMERCIAL CLINICAL TRIAL
Execution time: 07/09/2020 - 30/11/2021
PI: JOSE FERNANDO FLORIDO LOPEZ
CDC-Phase I / II, multicenter, randomized and controlled clinical trial to assess the safety and efficacy of intravenous administration of Expanded Allogeneic Adipose Tissue Adult Mesenchymal Stem Cells in patients with pneumonia
Funder: FUNDACION PUBLICA ANDALUZA PROGRESO Y SALUD
Type of test: INDEPENDENT CLINICAL TRIAL
Execution time: 21/04/2020 - 21/04/2021
PI: CARMEN HIDALGO TENORIO
CDC-Phase II and III, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Efficacy of ABBV -47D11 in Out-of-Hospital COVID-19 Adults
Funder: ABBVIE SPAIN SLU
Type of test: COMMERCIAL CLINICAL TRIAL
Execution time: 22/12/2020 -
PI: CARMEN HIDALGO TENORIO
A Randomized, Multi-center, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of Monoclonal Antibody VIR-7831 for the Early Treatment of Coronavirus Disease 2019 (COVID-19) in Non-hospitalized Patients
Funder: VIR BIOTECHNOLOGY INC
Type of test: COMMERCIAL CLINICAL TRIAL
Execution time: 30/10/2020 - 30/06/2021
PI: JUAN PASQUAU LIAÑO
Temocillin vs Meropenem for the Treatment of Third Generation Cephalosporin-Resistant Enterobacterial Bacteremia: A Randomized and Pragmatic Trial
Funder: ANDALUSIAN PUBLIC FOUNDATION FOR HEALTH RESEARCH MANAGEMENT OF SEVILLE
Type of test: INDEPENDENT CLINICAL TRIAL
Execution time: 20/10/2020 - 30/10/2020
IP: MIGUEL ANGEL LOPEZ RUZ
Sarilumab Clinical Trial in Hospitalized Adults With COVID-19 Presenting Cytokine Release Syndrome
Funder: UNIVERSITY FOUNDATION FOR THE DEVELOPMENT OF THE PROVINCE OF CORDOBA
Type of test: INDEPENDENT CLINICAL TRIAL
Execution time: 04/11/2020 -
PI: DAVID VINUESA GARCIA
Prospective, multicenter, randomized, open, uncontrolled clinical trial in relation (1: 1), of parallel groups, with subcutaneous immunotherapy in mixed polymerized presentation (100: 100), in patients with rhinoconjunctivitis sensitized to the following combination of pollen: Phleum Pratense and Olea Europaea and administered according to different guidelines
Funder: ROXALL MEDICINA ESPAÑA, SA
Type of test: COMMERCIAL CLINICAL TRIAL
Execution time: 29/07/2015 - 30/06/2016
PI: Mª ANGELES LARA JIMENEZ
Phase 2a, randomized, double-blind, placebo-controlled pilot study to investigate antiviral activity, clinical outcomes, safety, tolerability, and pharmacokinetics of two doses of JNJ-53718678 in non-hospitalized adult patients infected with respiratory syncytial virus
Funder: JANSSEN SCIENCES IRELAND UC
Type of test: COMMERCIAL CLINICAL TRIAL
Execution time: 10/01/2018 - 30/08/2020
PI: JUAN PASQUAU LIAÑO
Phase 2, randomized, double-blind, placebo-controlled study to evaluate the pharmacokinetics, safety and antiviral activity of JNJ-63623872 in combination with oseltamivir in adult and elderly adolescent patients hospitalized for influenza A infection.
Funder: JANSSEN-CILAG INTERNATIONAL NV
Type of test: COMMERCIAL CLINICAL TRIAL
Execution time: 02/11/2015 - 30/04/2017
IP: JOSE HERNANDEZ QUERO
Phase 2, randomized, double-blind, placebo-controlled study to evaluate the pharmacokinetics, safety and antiviral activity of JNJ-63623872 in combination with oseltamivir in adolescent, adult and elderly patients hospitalized for influenza A infection.
Funder: JANSSEN-CILAG INTERNATIONAL NV
Type of test: COMMERCIAL CLINICAL TRIAL
Execution time: 07/11/2016 - 30/04/2018
PI: JUAN PASQUAU LIAÑO
Phase 2b, randomized, double-blind, placebo-controlled study to evaluate antiviral activity, clinical outcomes, safety, tolerability, and pharmacokinetics of orally administered study drug regimens in hospitalized adult patients with respiratory syncytia virus infection.
Funder: JANSSEN-CILAG INTERNATIONAL NV
Type of test: COMMERCIAL CLINICAL TRIAL
Execution time: 03/11/2016 - 31/12/2018
PI: JUAN PASQUAU LIAÑO
Multicenter, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of SCY-078 Combination Therapy with Voriconazole in Patients With Invasive Pulmonary Aspergillosis (SCYNERGIA)
Funder: SYNEOS HEALTH IVH UK LIMITED (FORMERLY INVENTIV HEALTH CLINICAL UK LTD),
Type of test: COMMERCIAL CLINICAL TRIAL
Execution time: 23/09/2019 - 30/04/2020
PI: JUAN PASQUAU LIAÑO
Phase IIb, comparative, multicenter, randomized, double-blind study to evaluate the efficacy and safety of intravenous VIS410 administered together with oseltamivir (tamiflu) compared with oseltamivir as monotherapy in hospitalized adults with influenza A virus infection. that require oxygen support
Funder: VISTERRA INC
Type of test: COMMERCIAL CLINICAL TRIAL
Execution time: 21/12/2017 - 30/10/2019
IP: JOSE HERNANDEZ QUERO